Coronado Biosciences (CNDO) 2.28 $CNDO
Coronado Biosciences (CNDO) Looks Good: Stock Up 7.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 19, 8:39AM CST
Coronado Biosciences, Inc. (CNDO) was a big mover last session, as its shares rose over 7% on the day.
CNDO: 2.28 (+0.03), AMAG: 41.49 (+0.23)
Coronado Biosciences Reports on Separation of CB Pharma Acquisition Corp. Securities
GlobeNewswire - Tue Jan 06, 7:15AM CST
Coronado Biosciences, Inc. (Nasdaq:CNDO), founder of CB Pharma Acquisition Corp., reports on the separation of CB Pharma Acquisition Corp.'s (Nasdaq:CNLMU) securities into ordinary shares, rights and redeemable warrants, from the units.
CNDO: 2.28 (+0.03), CNLMU: 10.10 (-0.02)
Coronado Biosciences (CNDO) Rises: Stock Adds 6.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 7:44AM CST
Coronado Biosciences, Inc. (CNDO) was a big mover last session, as the company saw its shares rise over 6%
CNDO: 2.28 (+0.03), AFFX: 11.45 (+0.02)
Coronado Biosciences Announces Exercise of Portion of Over-Allotment Option in Conjunction With CB Pharma Acquisition Corp. IPO
GlobeNewswire - Mon Dec 29, 7:15AM CST
Coronado Biosciences, Inc. (Nasdaq:CNDO) ("Coronado" or the "Company"
, founder of CB Pharma Acquisition Corp., announced in connection with CB Pharma Acquisition Corp.'s public offering of 4,000,000 units, it has completed the sale of an additional 200,000 units pursuant to the 45-day over-allotment option granted to the underwriters in its public offering to purchase up to an additional 600,000 units. The issuance of the additional 200,000 units closed on December 24, 2014. The Company also consummated a simultaneous private placement of an additional 1,000 private placement units to EarlyBirdCapital, Inc.
CNDO: 2.28 (+0.03), CNLMU: 10.10 (-0.02)
Autism - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/rt9w3w/autism_pipeline) has announced the addition of the "Autism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Autism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - F. Hoffmann-La Roche - Sumitomo Dainippon Pharma - Egenix - Novartis - Merz Pharma GmbH & Co - Mitsubishi Tanabe Pharma Corporation - Teva Pharmaceutical Industries - BrainStorm Cell Therapeutics - Avanir Pharmaceuticals - Curemark - Coronado Biosciences - Omeros Corporation - Intra-Cellular Therapies - Cellceutix Corporation - Heptares Therapeutics - Edison Pharmaceuticals - Otsuka Holdings - Reviva Pharmaceuticals - Naurex - Mnemosyne Pharmaceuticals - BioCrea - Saniona - Confluence Pharmaceuticals - MedDay For more information visit http://www.researchandmarkets.com/research/rt...m_pipeline
CNDO: 2.28 (+0.03), TEVA: 56.77 (-0.58), ITCI: 24.53 (+2.45), BCLI: 3.86 (-0.02), OMER: 20.63 (+0.13), NVS: 102.20 (-0.17)
Coronado Biosciences Announces Closing of Initial Public Offering of CB Pharma Acquisition Corp.
GlobeNewswire - Thu Dec 18, 7:15AM CST
Coronado Biosciences, Inc. (Nasdaq:CNDO) ("Coronado" or the "Company" reports the closing on December 17, 2014 of the initial public offering of CB Pharma Acquisition Corp. (Nasdaq:CNLMU) ("CB Pharma" . CB Pharma is a Cayman Islands exempted company formed as a blank check company for the purpose of entering into a business combination with one or more businesses or entities, with a current focus in the specialty pharma and generic drug industries, among others.
CNDO: 2.28 (+0.03), CNLMU: 10.10 (-0.02)
Coronado prices CB Pharma IPO
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 9:58AM CST
CNDO: 2.28 (+0.03)
Coronado Biosciences Announces Pricing of Initial Public Offering of CB Pharma Acquisition Corp.
GlobeNewswire - Mon Dec 15, 7:15AM CST
Coronado Biosciences, Inc. (Nasdaq:CNDO) ("Coronado" or the "Company" reports the pricing on December 12, 2014 of the initial public offering of CB Pharma Acquisition Corp. (Nasdaq:CNLMU) ("CB Pharma" , a company which Coronado founded. CB Pharma is a Cayman Islands exempted company formed as a blank check company for the purpose of entering into a business combination with one or more businesses or entities, with a current focus in the specialty pharma and generic drug industries, among others.
CNDO: 2.28 (+0.03), CNLMU: 10.10 (-0.02)
Coronado Biosciences, Inc. (CNDO) in Focus: Stock Soars 17.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 28, 8:18AM CST
Coronado Biosciences, Inc. (CNDO) was a big mover last session, as the company saw its shares rise by nearly 18% on the day.
ANIP: 62.69 (-0.43), CNDO: 2.28 (+0.03), AMAG: 41.49 (+0.23), AFFX: 11.45 (+0.02)
Coronado Bio powers up in late trading
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 3:07PM CST
CNDO: 2.28 (+0.03)
Coronado Biosciences (CNDO) Jumps: Stock Rises 8.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 7:51AM CST
Coronado Biosciences, Inc. (CNDO) was a big mover last session, as its shares rose nearly 9% on the day.
BIIB: 391.66 (-0.45), CNDO: 2.28 (+0.03), ANIP: 62.69 (-0.43), AMAG: 41.49 (+0.23)
Warren Buffett Pick CBI Tumbles On Rating Downgrade
at The Street - Mon Nov 24, 12:00PM CST
Amicus Therapeutics, Inc. (NASDAQ:FOLD), Coronado Biosciences Inc (NASDAQ:CNDO) and Receptos Inc (NASDAQ:RCPT) hit midday posting major gains this Monday. Getting a sluggish start to the week are Fa...
CBI: 38.69 (+0.83), FATE: 5.00 (-0.07), CNDO: 2.28 (+0.03), RCPT: 115.83 (-0.66), FOLD: 8.36 (-0.11)
CB Pharma on deck for IPO
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 10:46AM CST
IPO: 24.00 (+0.09), BIS: 39.67 (-0.75), BIB: 141.30 (+2.39), CNDO: 2.28 (+0.03), IBB: 323.46 (+3.04), DRGS: 56.69 (unch), IXJ: 104.21 (+0.61), IRY: 49.63 (+0.34)
Rackspace Bounces, Making Dan Loeb $34 Million In The Process
at The Street - Tue Nov 11, 1:06PM CST
Coronado Biosciences Inc (NASDAQ:CNDO), Rackspace Hosting, Inc. (NYSE:RAX) and AuRico Gold Inc (NYSE:AUQ) are making notable climbs on the stock market this Tuesday. Town Sports International Holding...
RDUS: 50.37 (+0.63), CLUB: 6.94 (+0.10), RAX: 50.01 (+0.24), CNDO: 2.28 (+0.03), AUQ: 3.58 (-0.03)
InsiderInsights.com Daily Round Up 11/10/14: CHK, TWX, SGEN, PBFX
InsiderInsights - at Seeking Alpha - Tue Nov 11, 2:29AM CST
HAS: 62.74 (+0.58), VR: 42.10 (+0.07), SEIC: 43.20 (+0.07), DRNA: 21.30 (-0.06), HA: 18.72 (-0.31), SAM: 303.26 (-0.97), PBFX: 23.40 (+0.95), AMRI: 16.94 (-0.28), GSAT: 2.40 (+0.08), TNET: 36.49 (+0.76), TWX: 83.87 (+0.56), HLT: 28.57 (+0.13), Q: 63.31 (+0.06), SGEN: 31.57 (+0.36), CF: 301.40 (-1.20), OPK: 13.80 (-0.28), CHK: 21.08 (+0.58), CNDO: 2.28 (+0.03), CO: 4.75 (-0.06), CPLA: 65.23 (-1.37)
Coronado Biosciences Raises $3,500,000 Through the Private Placement of Restricted Common Stock
GlobeNewswire - Fri Nov 07, 7:38AM CST
Shares were sold at the closing price on November 6, 2014
CNDO: 2.28 (+0.03)
Coronado Biosciences Reports Financial Results
GlobeNewswire - Thu Nov 06, 6:08AM CST
Coronado Biosciences, Inc. (Nasdaq:CNDO) announced its financial results for the third quarter ended September 30, 2014. Coronado's net cash and restricted cash totaled $71.6 million and $15.4 million respectively at September 30, 2014. The Company posted a quarterly net loss of $4.6 million and $16.7 million, or $0.13 and $0.46 per share for the three and nine months ended September 30, 2014 respectively. These results compare to a net loss of $7.8 million and $27.4 million, or $0.24 and $0.95 per share for the three and nine months ended September 30, 2013 respectively.
CNDO: 2.28 (+0.03)
EC approves ulcerative colitis med
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 10:31AM CDT
SGYP: 2.98 (unch), JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87), CNDO: 2.28 (+0.03), PFE: 34.64 (-0.23), SHPG: 239.82 (+6.11), VBLX: 11.15 (+0.15), SLXP: 152.35 (+3.17), RCPT: 115.83 (-0.66), ABBV: 58.05 (+1.00), ATHX: 2.12 (unch)
Coronado Biosciences Forms Subsidiary to Acquire and License Dermatology Products for Commercialization
GlobeNewswire - Wed Oct 08, 7:35AM CDT
Coronado Biosciences, Inc. (Nasdaq:CNDO) has formed a wholly owned subsidiary, Journey Medical Corporation (JMC), to acquire and license dermatology products. Under the leadership of Claude Maraoui, CEO, JMC will begin building a portfolio of dermatological assets focused on acne, steroid responsive dermatoses, pigmentation and antifungals for promotion to dermatologists and pediatricians.
CNDO: 2.28 (+0.03)
Kamada Plunges Following Missed Marks In Trial
at The Street - Thu Sep 04, 11:52AM CDT
UTi Worldwide Inc. (NASDAQ:UTIW), Flexion Therapeutics Inc (NASDAQ:FLXN) and PVH Corp (NYSE
VH) are today's top-gaining billionaire stock picks midday. On the losing end are Kamada Ltd (NASDAQ:KM...
UTIW: 12.10 (+0.25), FLXN: 21.29 (+0.28), CNDO: 2.28 (+0.03), KMDA: 4.23 (+0.03), CIEN: 20.08 (+0.24), PVH: 106.54 (+1.13)
Coronado Biosciences (CNDO) Looks Good: Stock Up 7.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 19, 8:39AM CST
Coronado Biosciences, Inc. (CNDO) was a big mover last session, as its shares rose over 7% on the day.
CNDO: 2.28 (+0.03), AMAG: 41.49 (+0.23)
Coronado Biosciences Reports on Separation of CB Pharma Acquisition Corp. Securities
GlobeNewswire - Tue Jan 06, 7:15AM CST
Coronado Biosciences, Inc. (Nasdaq:CNDO), founder of CB Pharma Acquisition Corp., reports on the separation of CB Pharma Acquisition Corp.'s (Nasdaq:CNLMU) securities into ordinary shares, rights and redeemable warrants, from the units.
CNDO: 2.28 (+0.03), CNLMU: 10.10 (-0.02)
Coronado Biosciences (CNDO) Rises: Stock Adds 6.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 7:44AM CST
Coronado Biosciences, Inc. (CNDO) was a big mover last session, as the company saw its shares rise over 6%
CNDO: 2.28 (+0.03), AFFX: 11.45 (+0.02)
Coronado Biosciences Announces Exercise of Portion of Over-Allotment Option in Conjunction With CB Pharma Acquisition Corp. IPO
GlobeNewswire - Mon Dec 29, 7:15AM CST
Coronado Biosciences, Inc. (Nasdaq:CNDO) ("Coronado" or the "Company"
, founder of CB Pharma Acquisition Corp., announced in connection with CB Pharma Acquisition Corp.'s public offering of 4,000,000 units, it has completed the sale of an additional 200,000 units pursuant to the 45-day over-allotment option granted to the underwriters in its public offering to purchase up to an additional 600,000 units. The issuance of the additional 200,000 units closed on December 24, 2014. The Company also consummated a simultaneous private placement of an additional 1,000 private placement units to EarlyBirdCapital, Inc. CNDO: 2.28 (+0.03), CNLMU: 10.10 (-0.02)
Autism - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/rt9w3w/autism_pipeline) has announced the addition of the "Autism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Autism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - F. Hoffmann-La Roche - Sumitomo Dainippon Pharma - Egenix - Novartis - Merz Pharma GmbH & Co - Mitsubishi Tanabe Pharma Corporation - Teva Pharmaceutical Industries - BrainStorm Cell Therapeutics - Avanir Pharmaceuticals - Curemark - Coronado Biosciences - Omeros Corporation - Intra-Cellular Therapies - Cellceutix Corporation - Heptares Therapeutics - Edison Pharmaceuticals - Otsuka Holdings - Reviva Pharmaceuticals - Naurex - Mnemosyne Pharmaceuticals - BioCrea - Saniona - Confluence Pharmaceuticals - MedDay For more information visit http://www.researchandmarkets.com/research/rt...m_pipeline
CNDO: 2.28 (+0.03), TEVA: 56.77 (-0.58), ITCI: 24.53 (+2.45), BCLI: 3.86 (-0.02), OMER: 20.63 (+0.13), NVS: 102.20 (-0.17)
Coronado Biosciences Announces Closing of Initial Public Offering of CB Pharma Acquisition Corp.
GlobeNewswire - Thu Dec 18, 7:15AM CST
Coronado Biosciences, Inc. (Nasdaq:CNDO) ("Coronado" or the "Company"
reports the closing on December 17, 2014 of the initial public offering of CB Pharma Acquisition Corp. (Nasdaq:CNLMU) ("CB Pharma" . CB Pharma is a Cayman Islands exempted company formed as a blank check company for the purpose of entering into a business combination with one or more businesses or entities, with a current focus in the specialty pharma and generic drug industries, among others. CNDO: 2.28 (+0.03), CNLMU: 10.10 (-0.02)
Coronado prices CB Pharma IPO
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 9:58AM CST
CNDO: 2.28 (+0.03)
Coronado Biosciences Announces Pricing of Initial Public Offering of CB Pharma Acquisition Corp.
GlobeNewswire - Mon Dec 15, 7:15AM CST
Coronado Biosciences, Inc. (Nasdaq:CNDO) ("Coronado" or the "Company"
reports the pricing on December 12, 2014 of the initial public offering of CB Pharma Acquisition Corp. (Nasdaq:CNLMU) ("CB Pharma" , a company which Coronado founded. CB Pharma is a Cayman Islands exempted company formed as a blank check company for the purpose of entering into a business combination with one or more businesses or entities, with a current focus in the specialty pharma and generic drug industries, among others. CNDO: 2.28 (+0.03), CNLMU: 10.10 (-0.02)
Coronado Biosciences, Inc. (CNDO) in Focus: Stock Soars 17.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 28, 8:18AM CST
Coronado Biosciences, Inc. (CNDO) was a big mover last session, as the company saw its shares rise by nearly 18% on the day.
ANIP: 62.69 (-0.43), CNDO: 2.28 (+0.03), AMAG: 41.49 (+0.23), AFFX: 11.45 (+0.02)
Coronado Bio powers up in late trading
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 3:07PM CST
CNDO: 2.28 (+0.03)
Coronado Biosciences (CNDO) Jumps: Stock Rises 8.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 7:51AM CST
Coronado Biosciences, Inc. (CNDO) was a big mover last session, as its shares rose nearly 9% on the day.
BIIB: 391.66 (-0.45), CNDO: 2.28 (+0.03), ANIP: 62.69 (-0.43), AMAG: 41.49 (+0.23)
Warren Buffett Pick CBI Tumbles On Rating Downgrade
at The Street - Mon Nov 24, 12:00PM CST
Amicus Therapeutics, Inc. (NASDAQ:FOLD), Coronado Biosciences Inc (NASDAQ:CNDO) and Receptos Inc (NASDAQ:RCPT) hit midday posting major gains this Monday. Getting a sluggish start to the week are Fa...
CBI: 38.69 (+0.83), FATE: 5.00 (-0.07), CNDO: 2.28 (+0.03), RCPT: 115.83 (-0.66), FOLD: 8.36 (-0.11)
CB Pharma on deck for IPO
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 10:46AM CST
IPO: 24.00 (+0.09), BIS: 39.67 (-0.75), BIB: 141.30 (+2.39), CNDO: 2.28 (+0.03), IBB: 323.46 (+3.04), DRGS: 56.69 (unch), IXJ: 104.21 (+0.61), IRY: 49.63 (+0.34)
Rackspace Bounces, Making Dan Loeb $34 Million In The Process
at The Street - Tue Nov 11, 1:06PM CST
Coronado Biosciences Inc (NASDAQ:CNDO), Rackspace Hosting, Inc. (NYSE:RAX) and AuRico Gold Inc (NYSE:AUQ) are making notable climbs on the stock market this Tuesday. Town Sports International Holding...
RDUS: 50.37 (+0.63), CLUB: 6.94 (+0.10), RAX: 50.01 (+0.24), CNDO: 2.28 (+0.03), AUQ: 3.58 (-0.03)
InsiderInsights.com Daily Round Up 11/10/14: CHK, TWX, SGEN, PBFX
InsiderInsights - at Seeking Alpha - Tue Nov 11, 2:29AM CST
HAS: 62.74 (+0.58), VR: 42.10 (+0.07), SEIC: 43.20 (+0.07), DRNA: 21.30 (-0.06), HA: 18.72 (-0.31), SAM: 303.26 (-0.97), PBFX: 23.40 (+0.95), AMRI: 16.94 (-0.28), GSAT: 2.40 (+0.08), TNET: 36.49 (+0.76), TWX: 83.87 (+0.56), HLT: 28.57 (+0.13), Q: 63.31 (+0.06), SGEN: 31.57 (+0.36), CF: 301.40 (-1.20), OPK: 13.80 (-0.28), CHK: 21.08 (+0.58), CNDO: 2.28 (+0.03), CO: 4.75 (-0.06), CPLA: 65.23 (-1.37)
Coronado Biosciences Raises $3,500,000 Through the Private Placement of Restricted Common Stock
GlobeNewswire - Fri Nov 07, 7:38AM CST
Shares were sold at the closing price on November 6, 2014
CNDO: 2.28 (+0.03)
Coronado Biosciences Reports Financial Results
GlobeNewswire - Thu Nov 06, 6:08AM CST
Coronado Biosciences, Inc. (Nasdaq:CNDO) announced its financial results for the third quarter ended September 30, 2014. Coronado's net cash and restricted cash totaled $71.6 million and $15.4 million respectively at September 30, 2014. The Company posted a quarterly net loss of $4.6 million and $16.7 million, or $0.13 and $0.46 per share for the three and nine months ended September 30, 2014 respectively. These results compare to a net loss of $7.8 million and $27.4 million, or $0.24 and $0.95 per share for the three and nine months ended September 30, 2013 respectively.
CNDO: 2.28 (+0.03)
EC approves ulcerative colitis med
Seeking Alpha - at Seeking Alpha - Wed Oct 22, 10:31AM CDT
SGYP: 2.98 (unch), JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87), CNDO: 2.28 (+0.03), PFE: 34.64 (-0.23), SHPG: 239.82 (+6.11), VBLX: 11.15 (+0.15), SLXP: 152.35 (+3.17), RCPT: 115.83 (-0.66), ABBV: 58.05 (+1.00), ATHX: 2.12 (unch)
Coronado Biosciences Forms Subsidiary to Acquire and License Dermatology Products for Commercialization
GlobeNewswire - Wed Oct 08, 7:35AM CDT
Coronado Biosciences, Inc. (Nasdaq:CNDO) has formed a wholly owned subsidiary, Journey Medical Corporation (JMC), to acquire and license dermatology products. Under the leadership of Claude Maraoui, CEO, JMC will begin building a portfolio of dermatological assets focused on acne, steroid responsive dermatoses, pigmentation and antifungals for promotion to dermatologists and pediatricians.
CNDO: 2.28 (+0.03)
Kamada Plunges Following Missed Marks In Trial
at The Street - Thu Sep 04, 11:52AM CDT
UTi Worldwide Inc. (NASDAQ:UTIW), Flexion Therapeutics Inc (NASDAQ:FLXN) and PVH Corp (NYSE
VH) are today's top-gaining billionaire stock picks midday. On the losing end are Kamada Ltd (NASDAQ:KM... UTIW: 12.10 (+0.25), FLXN: 21.29 (+0.28), CNDO: 2.28 (+0.03), KMDA: 4.23 (+0.03), CIEN: 20.08 (+0.24), PVH: 106.54 (+1.13)
